Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Integrated traditional Chinese and Western medicine for triple-negative breast cancer
ChiCTR-IPR-16009517Phase 4Not yet recruiting
- Sponsor
- Longhua Hospital Shanghai University of Traditional Chinese Medicine
- Start
- Dec 2016
- Countries
- 1
01
Overview
Phase 4, randomised trial of bazhengsan in triple-negative breast cancer (TNBC) (2 arms), sponsored by Longhua Hospital Shanghai University of Traditional Chinese Medicine. Primary endpoints: Progression-free survival, 1-year survival rate and 1 more. Planned start Dec 2016; status: not yet recruiting.
02
Drugs
bazhengsan
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR-IPR-16009517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-16009517.